Richard A. Young - Sep 16, 2022 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Director
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Stock symbol
SYRS
Transactions as of
Sep 16, 2022
Transactions value $
$0
Form type
4
Date filed
9/19/2022, 05:16 PM
Previous filing
Sep 15, 2022
Next filing
Jan 11, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Stock Option (right to buy) Award $0 +12K $0.00 12K Sep 16, 2022 Common Stock 12K $7.35 Direct F1
transaction SYRS Restricted Stock Units Award $0 +8K $0.00 8K Sep 16, 2022 Common Stock 8K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.
F2 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F3 These RSUs will vest in three equal annual installments commencing on September 16, 2023. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.